Jim Cramer has advised investors to sell shares of Viking Therapeutics (NASDAQ: VKTX), despite the stock experiencing a notable 49% increase over the past year. This comes after a staggering 42% dip in August, followed by a subsequent recovery of 41%. However, concerns remain regarding the company's financial outlook, with Cramer and others warning that its growth potential may not justify the current market volatility.